Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexc.T

Text File | 1997-01-27 | 4KB | 2 lines

T cells,7,Talc,c27.9,Tamoxifen,5,Tanning booths,c37.8,Taste changes,p06.19;p17.22;p18.3;p18.16,Taxol,6,Taxotere,p35.13;c06.53,Technologist,p03.5,Tegretol,c05.26,Teratocarcinoma,c40.3,Teratoma ,4,Testis diagram,c40.5,Testis cancer,15,Testis self-examination,p34.17;c40.7,Testosterone,p23.16;p23.5;p23.19,Tetracycline,c27.9,delta-9-Tetrahydrocannabinol,p17.14,Therapeutic radiologist,p06.4,Therapeutic ratio,p06.6,Thiethylperazine,chr.p17.14,6-Thioguanine,c18.13,Thiosulfate,c29.20,Thiotepa,p11.5;c06.53;c25.15;c29.20,Thoracoscopy,p05.5,Thymoma,c41.1,Thymus,c41.1,Thymus cancer,12,Thyroid cancer,14,Thyroid gland diagram,c42.6,Thyroidectomy,c42.14,Thyroiditis,c42.5,Tissue expansion breast reconstruction,rec.6,TNM system of staging,p01.17,Tobacco,2,Too Young To Have Cancer Toronto,p16.17,Topoisomerase I inhibitors,p35.8,Topotecan,p35.11;c06.53,Toremifene,p35.13,Toxic shock syndrome,p11.5,Toxicity bone marrow,p12.10,Tracheal obstruction,p09.6,Tranquilizers,p17.23,Transitional cell carcinoma,c02.1;c04.1;c35.32,Transplant center,p12.14,Transverse rectus abdominus myocutaneous flap technique,rec.6,Tranylcypromine sulfate,c08.14,Treatment,6,Treatment options,9,Tretinoin,p35.13,Trichomonas,c02.3,Trophoblastic disease,12,Tuberculosis,c05.21,Tuberous sclerosis,c05.2;c36.4,Tubular carcinoma,c06.3,Tumor,27,Tumor Board,p04.11,Tumor cell modulation immunotherapy,p08.6,Tumor infiltrating lymphocytes (TIL cells),p08.8;c25.19,Tumor markers,2,Tumor names understanding,p01.12,Tumor necrosis factor (TNF),6,Tumor vaccines,p08.10;p08.17;p35.17;c25.17,Turner's syndrome,c40.4,
defined,p04.5,gene therapy,p08.12,immune response,p08.3;p20.2,immunotherapy,p08.9,killer,p08.5,lymphomas,c24.1,suppressor,p08.4,for breast cancer,c06.24;c06.27;c06.42,for ovarian cancer,c29.21,for uterine cancer,c44.20,for vaginal cancer,c46.13,related drug,p35.8,for breast cancer,c06.53,for ovarian cancer,c29.14,for uterine cancer,c44.21,investigated,p35.5,related drug,p35.13,side effects,chr.p17.13,child,c10a.2,immature,c30.1,testis,c40.2,thyroid,c42.2,causes,c40.4,diagnosis,p34.17;c40.12,follow-up,c40.25,questions to ask,c40.29,recurrence,c40.28,risk factors,c40.5,screening,c40.7,and sexuality,p23.7,spread,c40.3,staging,c40.15,symptoms,c40.8,treatment,c40.16,tumor markers,c40.9,types,c40.1,unknown primary site,c07.1,causes,c41.1,diagnosis,c41.6,follow-up,c41.11,questions to ask,c41.13,recurrence,c41.12,risk factors,c41.3,screening,c41.4,spread,c41.2,staging,c41.7,symptoms,c41.5,treatment,c41.8,types,c41.1,causes,c42.3,child,c10a.2,diagnosis,c42.9,follow-up,c42.25,questions to ask,c42.28,recurrence,c42.26,risk factors,c42.4,screening,c42.6,spread,c42.3,staging ,c42.13,symptoms,c42.8,treatment,c42.14,types,c42.1,unknown primary site,c07.3;c07.6,irritates mouth,p17.19,risk factor,p01.7;p34.9;p34.15;c04.4;c14b.20;c17.3;c20.3,advances in,p33.7,future options,p33.10,genetic,p36.9,health care team,p03.4,PDQ guidelines,p37.3,and staging,p01.19,adjuvant therapy,p04.6,biological therapy,p04.5,chemotherapy,p04.4,choosing,p04.9,clinical trials,p04.17,combination therapies,p04.6,radiation therapy,p04.4,second opinions,p04.16,surgery,p04.3,causes,c43.3,diagnosis,c43.8,follow-up,c43.17,questions to ask,c43.19,recurrence,c43.17,risk factors,c43.5,screening,c43.7,spread,c43.3,staging,c43.11,symptoms,c43.8,treatment,c43.13,types,c43.2,ACTH-producing,c34.1,APUD,c08.3;c21.2,basaloid,c02.1,benign,p01.4,clear cell,c25.5;c29.1;c32.2;c44.2,cytological tests,p02.19,endodermal,c30.1;c30.6;c46.1;c46.13,growth hormone-producing,c34.1,growth rate,p01.3;p01.15,high-grade,p01.16,low-grade,p01.16,malignant,p01.4;p01.12,midline,c07.13,mixed,c45.1,neuroendocrine,c08.1,non-functioning,c34.7,prolactin-producing,c34.1,pure,c45.1,recurrent,p05.6,residual,p05.6,solid,p35.11,spreading,p01.10,superficial,c04.2,types,p01.12,undifferentiated,p01.15,urachal,c04.3,well-differentiated,p01.15,testis,c40.9,tests for,p02.7,for bladder cancer,c04.18,for kidney cancer,c17.11,in biological therapy,p08.11,in hyperthermic perfusion,p11.5,investigational,p35.11,side effects,p08.17,